According to a new report from HealthPocket
Obamacare’s Out-of-Pocket Costs for Specialty Drugs Increases 16% in One Year
Out-of-pocket costs for specialty drugs under the Affordable Care Act increased 16 percent from 2016 to 2017, according to a report from HealthPocket.
While prescription drug coverage comes standard with Obamacare plans, not all medications prescribed to individuals will be paid for.
«For a plan to help pay for a drug, the drug must first be included on the health plan’s formulary,» the report states. «Drugs that are off-formulary are not only paid for completely out-of-pocket by the enrollee but those expenses do not count towards the annual cap on out-of-pocket spending.»
The report found that for Obamacare’s silver plan, a Humira Pen, a specialty drug that treats arthritis and Crohn’s disease, will total $1,889.66 in out-of-pocket costs, which increased $262.45 in price since 2016. Harvoni, a specialty drug used to treat those with hepatitis C, will total $12,590.60 in out-of-pocket costs, which increased by $1,762.59 in one year.
«Compared to the coinsurance rate for 2016, average cost-sharing for specialty drugs on silver plans rose 16 percent in 2017,» the report states. «This increase in monthly out-of-pocket costs for the top five specialty drugs ranged from $226.29 to $1,762.59. The average cap on yearly out-of-pocket costs on 2017 silver plans is $6,449 for an individual and $12,952 for families.»
In addition, copayments are high for specialty drugs for those with silver plans. The report found that the average copayment for specialty drugs was $261.55.
«Recent political debate on continuing $7 billion in annual cost-sharing subsidies largely ignored other substantial issues regarding Affordable Care Act out-of-pocket expenses,» the report states. «Aside from matters such as deductibles faced by unsubsidized enrollees, there are also enduring concerns regarding out-of-pocket costs for prescription medications.»
According to the head of research at HealthPocket, if individuals are taking these types of specialty drugs they should be considering high out-of-pocket costs.
«As out-of-pocket costs for specialty drugs continue to be a problem without resolution, consumers taking these medications need to be vigilant in their insurance shopping,» says Kev Coleman, head of research and data at the company. «For these consumers, cost-sharing for specialty drugs and annual caps on out-of-pocket expenses can be even more important factors than premiums when financially comparing health plans.»